tm logo
DRIVIXTI
Live/Pending
SECOND EXTENSION - GRANTED

granted

on 26 Jun 2024

Last Applicant/ Owned by

Route 206 & Province Line Road

Princeton

NJ

08543

Serial Number

97351687 filed on 07th Apr 2022

Registration Number

N/A

Correspondent Address

Marilyn F. Kelly

Marilyn F. Kelly BRISTOL-MYERS SQUIBB COMPANY

TRADEMARK DEPT., MAILSTOP D.4243

PRINCETON, NJ 08648-4000

United States

Filing Basis

1. intent to use

2. intent to use current

Disclaimer

NO DATA

DRIVIXTI

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloprol Read More

Classification Information


Class [005]
Pharmaceutical Products


Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use


First Use Date in General

N/A

First Use Date in Commerce

N/A

Mark Details


Serial Number

No 97351687

Mark Type

No Service/Collective Mark

Attorney Docket Number

No 00161306-US

44D Filed

No

44D Current

No

44E filed

No

44E Current

No

66A Filed

No

66A Current

No

Current Basis

No

No Basis

No

Legal History


Show more

Status DateAction Taken
11th Dec 2024SOU TEAS EXTENSION RECEIVED
26th Jun 2024SOU EXTENSION 2 FILED
26th Jun 2024SOU EXTENSION 2 GRANTED
26th Jun 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
26th Jun 2024SOU TEAS EXTENSION RECEIVED
04th Jan 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
02th Jan 2024SOU EXTENSION 1 GRANTED
02th Jan 2024SOU EXTENSION 1 FILED
02th Jan 2024SOU TEAS EXTENSION RECEIVED
02th Aug 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED